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We have conducted a bibliometric review of drug repurposing by scanning >25 million papers in
PubMed and using text-mining methods to gather, count and analyze chemical–disease therapeutic
relationships. We find that >60% of the 35,000 drugs or drug candidates identified in our study have
been tried in more than one disease, including 189 drugs that have been tried in >300 diseases each.
Whereas in the majority of cases these drugs were applied in therapeutic areas close to their original use,
there have been striking, and perhaps instructive, successful attempts of drug repurposing for
unexpected, novel therapeutic areas.
Introduction
Drug repurposing (also known as repositioning, reprofiling, redir-
ecting or rediscovering [1]) is defined as developing new uses for a
drug beyond its original use or initial approved indication. Drug
repurposing has attracted increasing attention in recent years as
drug companies seek potentially inexpensive alternatives to com-
pensate for the high costs and disappointing success rate associat-
ed with the drug discovery pipeline [2]. Repurposing can help
identify new therapies for diseases at lower cost and in a shorter
time, particularly in those cases where preclinical safety studies
have already been completed.
During recent years, several authors have reviewed drug repur-
posing [2–10]. These reviews for the most part analyze and describe
the methodologies, often illustrated with examples of successful
repurposing. The compelling case of the repurposing of sildenafil
(Viagra1) for erectile dysfunction is common knowledge but there
are other stories of repurposing that have gone on to be profitable:
bupropion, originally used for depression, was repurposed for
smoking cessation; and thalidomide, once a treatment for morn-
ing sickness, is now used for multiple myeloma.
Herein, we report on a bibliometric analysis of drug repurposing
conducted with the aim of measuring and understanding the
scope of the practice over the history of modern drug discovery.
We define repurposing as a PubMed report of the use or testing of a
drug for a disease different from the originally reported one.
Although inexact, this methodology gives unique insight into
the scope of the practice. By examining a few drugs in-depth
we see striking examples of reasoning and intuition applied to
repurposing.
Literature analysis
Our analysis was based on PubMed’s MEDLINE data (http://www.
ncbi.nlm.nih.gov/pubmed). At >25 million entries, PubMed is the
largest and most comprehensive source of biomedical research
citations. To assemble a dataset for this bibliometric analysis,
we built on earlier text-mining work [11] and identified articles
in PubMed where a chemical entity was described in terms of
its therapeutic association with a disease. We determined this
relationship by examining the MeSH annotations in a stepwise
manner (described in the supplementary material online).
These chemical entities represent drugs or drug candidates. For
simplicity, these entities will be referred to here as drugs.
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